Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.49 |
| ▸ | STAT6 | P42226 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 5/20 | 0.45 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11025081 | 0.91 | STAT6 (0.55) | MAPKAPK2SLC2A1STAT6PTK2EGFR | |
| SCHEMBL11028029 | 0.90 | CDK4 (0.53) | MAPKAPK2SLC2A1STAT6PTK2EGFR | |
| SCHEMBL11029481 | 0.90 | SLC2A1 (0.52) | MAPKAPK2SLC2A1STAT6PTK2EGFR | |
| SCHEMBL11029543 | 0.90 | MAPKAPK2 (0.49) | MAPKAPK2SLC2A1STAT6EGFRJAK3 | |
| SCHEMBL11031933 | 0.88 | MAPKAPK2 (0.51) | MAPKAPK2SLC2A1STAT6PTK2EGFR | |
| SCHEMBL11029790 | 0.88 | MAPKAPK2 (0.52) | MAPKAPK2SLC2A1STAT6PTK2EGFR | |
| SCHEMBL11029564 | 0.86 | TNIK (0.52) | SLC2A1STAT6PTK2EGFRSYK | |
| SCHEMBL11029285 | 0.86 | SLC2A1 (0.49) | MAPKAPK2SLC2A1STAT6PTK2EGFR | |
| SCHEMBL11027579 | 0.85 | SLC2A1 (0.49) | MAPKAPK2SLC2A1STAT6PTK2EGFR | |
| SCHEMBL11030740 | 0.85 | SLC2A1 (0.55) | MAPKAPK2SLC2A1STAT6PTK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | claimed |
| CN-103380117-A | Picolinamide inhibitors of kinases | ABBOTT LAB | 2013-10-30 | — | — | CN | claimed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | claimed |
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2665711-A1 | PICOLINAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| CN-103380117-A | Picolinamide inhibitors of kinases | ABBOTT LAB | 2013-10-30 | — | — | CN | disclosed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012100135-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ALK, PKN2, ERBB2 | MAPKAPK2 115/4885SLC2A1 3662/4885STAT6 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.